Long‐term safety of vedolizumab for inflammatory bowel disease
Alimentary Pharmacology & Therapeutics2020Vol. 52(8), pp. 1353–1365
Citations Over TimeTop 1% of 2020 papers
Edward V. Loftus, Brian G. Feagan, Remo Panaccione, Jean‐Frédéric Colombel, William J. Sandborn, Bruce E. Sands, Silvio Danese, Geert D’Haens, David T. Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A. Lirio, Séverine Vermeire
Abstract
The safety profile of vedolizumab remains favourable with no unexpected or new safety concerns. These results further establish the safety of vedolizumab and support its long-term use (NCT00790933/EudraCT 2008-002784-14).
Related Papers
- → Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety(2018)48 cited
- → Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab(2020)5 cited
- → Vedolizumab for the treatment of ulcerative colitis(2015)2 cited
- → Vedolizumab for induction and maintenance of remission in Crohn’s disease(2020)1 cited
- → Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial(2018)1 cited